TSRI Researchers Explore Ways That a Drug Like Avandia Can Be Made Safer

JUPITER, FL – September 28, 2017 – With the heightened concerns over the dangerous side effects of the once-popular antidiabetic drug Avandia, researchers at The Scripps Research Institute (TSRI) in Jupiter, Florida, are working to understand how small molecules, like those in Avandia, can have such varied effects throughout the body. The insights could help researchers design new drugs with better efficacy and fewer side effects.

MORE “TSRI Researchers Explore Ways That a Drug Like Avandia Can Be Made Safer”

‘OUT-OF-THE-BOX’ THINKING MAY BUILD A BETTER BRAIN

More than 5 million Americans today are affected by Alzheimer’s disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million people with AD worldwide by 2050. In the past 25 years, only five symptomatic medications for AD have met their primary clinical endpoints in Phase III clinical trials and successfully come to market; of these, four are still available.

MORE “‘OUT-OF-THE-BOX’ THINKING MAY BUILD A BETTER BRAIN”

BOCA RATON REGIONAL HOSPITAL OFFERS MRI-GUIDED PROSTATE BIOPSIES

Boca Raton Regional Hospital’s Eugene M. & Christine E. Lynn Cancer Institute has announced that it is now offering a new method to biopsy suspected prostate tumors by fusing MRI images of the gland with information derived through transrectal ultrasound (TRUS). The procedure provides for a much more efficient and effective manner to localize and determine clinically significant, high-grade tumors in the prostate.

MORE “BOCA RATON REGIONAL HOSPITAL OFFERS MRI-GUIDED PROSTATE BIOPSIES”

NIH GRANT TO FURTHER NEUROPSYCHIATRIC DISORDERS RESEARCH

Alterations in a naturally occurring chemical in the brain called serotonin have been linked to a number of neuropsychiatric disorders including depression, anxiety, obsessive-compulsive disorder as well as autism spectrum disorder (ASD). Randy Blakely, Ph.D., executive director of Florida Atlantic University’s Brain Institute and a professor of biomedical science in FAU’s Charles E. Schmidt College of Medicine, and his team, have been studying this mood-regulating gene in the brain that carries signals across the synapse, or the gap between nerve cells. The supply of serotonin is tightly regulated by the serotonin transporter (SERT) and inappropriate shifts in SERT activity can have dramatic consequences.

MORE “NIH GRANT TO FURTHER NEUROPSYCHIATRIC DISORDERS RESEARCH”

SANCILLO GETS RARE PEDIATRIC DISEASE DESIGNATION FOR SICKLE CELL DISEASE TREATMENT

 

Sancilio Pharmaceuticals Company, Inc. (SPCI) announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Altemia Soft Gelatin Capsules for the treatment of sickle cell disease (SCD) in children. The designation comes with a bit of good timing, as September is National Sickle Cell Awareness Month. The awareness effort was first officially recognized by the federal government in 1983.

MORE “SANCILLO GETS RARE PEDIATRIC DISEASE DESIGNATION FOR SICKLE CELL DISEASE TREATMENT”

Scripps Florida Scientist Awarded $2.5 Million Collaborative Grant to Develop New Diabetes Treatment

JUPITER, FL – September 19, 2017 – Patrick R. Griffin, co-chair of the Department of Molecular Medicine on the Florida campus of The Scripps Research Institute (TSRI), has been awarded a $2.5 million collaborative grant with Brigham and Women’s Hospital by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health (NIH).

MORE “Scripps Florida Scientist Awarded $2.5 Million Collaborative Grant to Develop New Diabetes Treatment”